表紙:糖尿病治療薬の世界市場 (2022年-2027年):市場規模・産業動向・シェア・成長率・インサイト・COVID-19の影響・企業分析
市場調査レポート
商品コード
1066784

糖尿病治療薬の世界市場 (2022年-2027年):市場規模・産業動向・シェア・成長率・インサイト・COVID-19の影響・企業分析

Diabetes Drug Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis

出版日: | 発行: Renub Research | ページ情報: 英文 140 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.03円
糖尿病治療薬の世界市場 (2022年-2027年):市場規模・産業動向・シェア・成長率・インサイト・COVID-19の影響・企業分析
出版日: 2022年03月01日
発行: Renub Research
ページ情報: 英文 140 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の糖尿病治療薬の市場規模は、2021年の631億3,000万米ドルから、予測期間中は4.6%のCAGRで推移し、2027年には829億2,000万米ドルの規模に成長すると予測されています。

糖尿病治療薬は、近年、すべての年齢層で糖尿病の有病率が上昇しているため、使用頻度が高くなっています。人口の高齢化、技術の進歩、新規薬剤の販売の増加などの要因も同市場の成長を推進しています。また、糖尿病と闘うための政府の取り組みも市場成長を後押ししています。一方で、医薬品やインスリンデバイスの製造コストの高さ、糖尿病治療に関する一般の意識の低さなどが同市場のさらなる成長を抑制しています。

当レポートでは、世界の糖尿病治療薬の市場を調査し、市場概要、市場成長への影響因子の分析、市場規模の推移・予測、疾患タイプ・経口剤・注射剤・インスリン・地域など各種区分別の詳細分析、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査・調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長要因
  • 課題

第5章 世界の糖尿病治療薬市場

第6章 市場シェア:世界の糖尿病治療薬市場

  • 疾患タイプ別
  • 薬剤タイプ別 (経口剤・注射剤・インスリン)
  • 経口剤別
  • 注射剤別
  • インスリン別
  • 地域別

第7章 世界の糖尿病治療薬市場:疾患タイプ別

  • 1型糖尿病薬
  • 2型糖尿病薬

第8章 世界の糖尿病治療薬市場:薬剤タイプ別

  • 経口剤
    • (DPP) IV阻害剤
    • SGLT-2
    • アルファグルコシダーゼ阻害剤
    • ビグアニド
    • その他
  • 注射剤
    • グルカゴン様ペプチド (GLP) 1アゴニスト
    • アミリン受容体アゴニスト
  • インスリン
    • 速効型インスリン
    • 長時間作用型インスリン
    • プレミックスインスリン
    • その他

第9章 世界の糖尿病治療薬市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 中東・アフリカ

第10章 ポーターズファイブフォース分析

第11章 企業の分析

  • Novo Nordisk
  • AstraZeneca plc
  • Biocon
  • Sanofi
  • Eli Lilly
  • Johnson & Johnson
  • Bristol Myers Squibb Co.
図表

List of Figures

  • Figure-01: Global - Diabetes Drug Market (Million US$), 2016 - 2021
  • Figure-02: Global - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
  • Figure-03: Disease Type - Type 1 Diabetes Drug Market Market (Million US$), 2016 - 2021
  • Figure-04: Disease Type - Forecast for Type 1 Diabetes Drug Market Market (Million US$), 2022 - 2027
  • Figure-05: Disease Type - Type 2 Diabetes Drug Market Market (Million US$), 2016 - 2021
  • Figure-06: Disease Type - Forecast for Type 2 Diabetes Drug Market Market (Million US$), 2022 - 2027
  • Figure-07: Oral - (DPP) IV inhibitor Market (Million US$), 2016 - 2021
  • Figure-08: Oral - Forecast for (DPP) IV inhibitor Market (Million US$), 2022 - 2027
  • Figure-09: Oral - SGLT - 2 Market (Million US$), 2016 - 2021
  • Figure-10: Oral - Forecast for SGLT - 2 Market (Million US$), 2022 - 2027
  • Figure-11: Oral - Alpha Glucosidase Inhibitor Market (Million US$), 2016 - 2021
  • Figure-12: Oral - Forecast for Alpha Glucosidase Inhibitor Market (Million US$), 2022 - 2027
  • Figure-13: Oral - Biguanide Market (Million US$), 2016 - 2021
  • Figure-14: Oral - Forecast for Biguanide Market (Million US$), 2022 - 2027
  • Figure-15: Oral - Others Oral Drug Market (Million US$), 2016 - 2021
  • Figure-16: Oral - Forecast for Others Oral Drug Market (Million US$), 2022 - 2027
  • Figure-17: Injection - Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2016 - 2021
  • Figure-18: Injection - Forecast for Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2022 - 2027
  • Figure-19: Injection - Amylin receptor agonist Market (Million US$), 2016 - 2021
  • Figure-20: Injection - Forecast for Amylin receptor agonist Market (Million US$), 2022 - 2027
  • Figure-21: Insulin - Rapid - Acting Insulin Market (Million US$), 2016 - 2021
  • Figure-22: Insulin - Forecast for Rapid - Acting Insulin Market (Million US$), 2022 - 2027
  • Figure-23: Insulin - Long Acting Insulin Market (Million US$), 2016 - 2021
  • Figure-24: Insulin - Forecast for Long Acting Insulin Market (Million US$), 2022 - 2027
  • Figure-25: Insulin - Premixed Insulin Market (Million US$), 2016 - 2021
  • Figure-26: Insulin - Forecast for Premixed Insulin Market (Million US$), 2022 - 2027
  • Figure-27: Insulin - Other Insulin Market (Million US$), 2016 - 2021
  • Figure-28: Insulin - Forecast for Other Insulin Market (Million US$), 2022 - 2027
  • Figure-29: America - Diabetes Drug Market (Million US$), 2016 - 2021
  • Figure-30: America - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
  • Figure-31: Europe - Diabetes Drug Market (Million US$), 2016 - 2021
  • Figure-32: Europe - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
  • Figure-33: Asia Pacific - Diabetes Drug Market (Million US$), 2016 - 2021
  • Figure-34: Asia Pacific - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
  • Figure-35: Middle East & Africa - Diabetes Drug Market (Million US$), 2016 - 2021
  • Figure-36: Middle East & Africa - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
  • Figure-37: Novo Nordisk - Global Revenue (Million US$), 2016 - 2021
  • Figure-38: Novo Nordisk - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-39: AstraZeneca plc - Global Revenue (Million US$), 2016 - 2021
  • Figure-40: AstraZeneca plc - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-41: Biocon - Global Revenue (Million US$), 2016 - 2021
  • Figure-42: Biocon - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-43: Sanofi - Global Revenue (Million US$), 2016 - 2021
  • Figure-44: Sanofi - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-45: Eli Lilly - Global Revenue (Million US$), 2016 - 2021
  • Figure-46: Eli Lilly - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-47: Johnson & Johnson - Global Revenue (Million US$), 2016 - 2021
  • Figure-48: Johnson & Johnson - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-49: Bristol Myers Squibb Co. - Global Revenue (Million US$), 2016 - 2021
  • Figure-50: Bristol Myers Squibb Co. - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables

  • Table-01: Global - Diabetes Drug Market Share by Disease Type (Percent), 2016 - 2021
  • Table-02: Global - Forecast for Diabetes Drug Market Share by Disease Type (Percent), 2022 - 2027
  • Table-03: Global - Diabetes Drug Market Share by Therapy (Percent), 2016 - 2021
  • Table-04: Global - Forecast for Diabetes Drug Market Share by Therapy (Percent), 2022 - 2027
  • Table-05: Global - Diabetes Drug Market Share by Oral Drug (Percent), 2016 - 2021
  • Table-06: Global - Forecast for Diabetes Drug Market Share by Oral Drug (Percent), 2022 - 2027
  • Table-07: Global - Diabetes Drug Market Share by Injection Drug (Percent), 2016 - 2021
  • Table-08: Global - Forecast for Diabetes Drug Market Share by Injection Drug (Percent), 2022 - 2027
  • Table-09: Global - Diabetes Drug Market Share by Insulin (Percent), 2016 - 2021
  • Table-10: Global - Forecast for Diabetes Drug Market Share by Insulin (Percent), 2022 - 2027
  • Table-11: Global - Diabetes Drug Market Share by Region (Percent), 2016 - 2021
  • Table-12: Global - Forecast for Diabetes Drug Market Share by Region (Percent), 2022 - 2027
目次

Global Diabetes Drug Market is estimated to reach US$ 82.92 Billion in 2027. Diabetes is a long-term condition indicated by high blood sugar levels. It is caused by a malfunction in the pancreas, which secretes insulin. Besides, diabetes is also referred to as diabetes mellitus. High blood sugar levels cause thirst, hunger, and frequent urination. Diabetes complications such as diabetes ketoacidosis, heart disease, stroke, and kidney failure are caused by a lack of treatment. Diabetes is treated with insulin infusion therapy-diabetes medications aid in preventing complications and controlling blood glucose levels. Metformin, Actos, Avandia, Lantus subcutaneous, and invokana are medications used to treat type 2 diabetes. All medicines are taken orally except for insulin, exenatide, liraglutide, and pramlintide.

Worldwide Diabetes Drug Market Size was US$ 63.13 Billion in 2021

Diabetes drugs have been used more frequently in recent years as the prevalence of diabetes has increased across all age groups. Some of the critical elements driving growth in the diabetes drugs market include an aging population, technological advancements, and increased sales of novel drugs.

Besides, government initiatives to combat diabetes are fueling the growth of the diabetes drugs market. The high manufacturing costs of drugs and insulin devices, on the other hand, are limiting the development of the diabetes drugs market. Furthermore, a lack of public awareness about diabetes treatment impedes the growth of the diabetes drugs market. As per Renub Research, Global Diabetes Drug Industry will expand with a CAGR of 4.6% during 2021-2027.

Synopsis of COVID-19 Impact on the Global Diabetes Drug Market:

The appearance of COVID-19 had brought the world to a halt. The healthcare crisis had a far-reaching impact on businesses across industries. The pandemic underscored the importance of chronic disease management and its role in public health. People with diabetes were at the highest risk of becoming infected with the virus. As a result, population healthcare systems have prioritized infrastructure consolidation to improve chronic disease care. As a result, the current drug market is boosted, encouraging R&D investments. Furthermore, increased public awareness aided patients in making more clinically informed decisions about the pharmacological therapies required.

Disease Type: Type 2 Diabetes Holds Prominent Position:

Our report classifies the diabetes drug market into type 1 diabetes and type 2 diabetes. Remarkably, due to higher prevalence worldwide, type 2 diabetes contributes significantly to the diabetes drugs market. Furthermore, rising obesity rates, rising disposable income, and improved healthcare facilities are some of the key factors driving the growth of the diabetes type 2 segment. Meanwhile, type 1 diabetes is expected to follow the type 2 segment and rise rapidly during the forecast period.

By Therapy, the Market for Insulin Remains Dominant:

In this report, we have furnished a comprehensive analysis of the global diabetes drug market and divided it into three segments: Oral, Injectable, and Insulin. According to our research, the demand for insulin remains dominant, owing to imperfect competition from biosimilars in the market and patients' lack of trust in biosimilars.

In addition, we have examined the sub-segments for the segments as mentioned earlier based on therapy. Precisely, (DPP) IV inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, and Biguanide are Oral Drug sub-segments, Glucagon-like peptide (GLP) 1 agonist, and Amylin receptor agonist are Injection Drug sub-segments and Rapid - Acting Insulin, Long-Acting Insulin, and Premixed Insulin are Insulin sub-segments covered in our report.

The America Accounts for Lion's Share:

America holds the lion's share in 2021 and is expected to maintain its dominance throughout the forecast period. This is primarily due to an increase in the diabetes population in the American region due to stress, unhealthy diets, and obesity. Besides, there are over million diabetes patients in the American region, and this number is expected to ascend in the forthcoming years, according to our analysis.

Furthermore, the growth of the diabetes drug market in this region is aided by favorable government reimbursement policies and advanced healthcare infrastructure. Aside from that, Asia-Pacific countries are expected to generate higher demand in the coming years, owing primarily to initiatives undertaken by local governments and health organizations to raise awareness about diabetes, drugs, and devices.

Competitive Landscape:

The diabetes drugs market is relatively fragmented, with only major and generic players. The few significant players studied in our report include Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, and Bristol Myers Squibb Co. The competition among the participants is high, as each is attempting to develop new drugs and offer them at competitive prices. Furthermore, players are expanding into new markets to increase their market share, particularly in emerging economies where demand exceeds supply.

Renub Research latest report "Diabetes Drug Market, Global Forecast By Disease Type (Type 1 Diabetes Drug Market and Type 2 Diabetes Drug Market), Therapy (Oral ((DPP) IV inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, and Biguanide), Injection (Glucagon-like peptide (GLP) 1 agonist, and Amylin receptor agonist), Insulin (Rapid - Acting Insulin, Long-Acting Insulin, and Premixed Insulin ), Region ( America, Europe, Asia Pacific, The Middle East & Africa), Companies (Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, and Bristol Myers Squibb Co)" provides a detailed analysis of Diabetes Drug Industry.

Disease Type - Market has been covered from 2 viewpoints:

  • 1. Type 1 Diabetes Drug Market
  • 2. Type 2 Diabetes Drug Market

Therapy - Market have been covered from 3 viewpoints:

  • 1. Oral
    • (DPP) IV inhibitor
    • SGLT - 2
    • Alpha Glucosidase Inhibitor
    • Biguanide
    • Others Oral Drug
  • 2. Injection
    • Glucagon-like peptide (GLP) 1 agonist
    • Amylin receptor agonist
  • 3. Insulin
    • Rapid - Acting Insulin
    • Long Acting Insulin
    • Premixed Insulin
    • Other Insulin

Region - Market have been covered from 4 viewpoints:

  • 1. North America
  • 2. Europe
  • 3. Asia Pacific
  • 4. Middle East & Africa

Company Insights:

  • Overview
  • Recent Development & Strategies
  • Financial Insights

Companies Covered:

  • 1. Novo Nordisk
  • 2. AstraZeneca plc
  • 3. Biocon
  • 4. Sanofi
  • 5. Eli Lilly
  • 6. Johnson & Johnson
  • 7. Bristol Myers Squibb Co.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Diabetes Drugs Market

6. Market Share - Global Diabetes Drugs Market

  • 6.1 By Disease Type
  • 6.2 By Therapy - (Oral, Injection, Insulin)
  • 6.3 By Oral Drug
  • 6.4 By Injection Drug
  • 6.5 By Insulin
  • 6.6 By Regions

7. Disease Type - Global Diabetes Drugs Market

  • 7.1 Type 1 Diabetes Drug Market
  • 7.2 Type 2 Diabetes Drug Market

8. Therapy - Global Diabetes Drugs Market

  • 8.1 Oral
    • 8.1.1 (DPP) IV inhibitor
    • 8.1.2 SGLT - 2
    • 8.1.3 Alpha Glucosidase Inhibitor
    • 8.1.4 Biguanide
    • 8.1.5 Others Oral Drug
  • 8.2 Injection
    • 8.2.1 Glucagon-like peptide (GLP) 1 agonist
    • 8.2.2 Amylin receptor agonist
  • 8.3 Insulin
    • 8.3.1 Rapid - Acting Insulin
    • 8.3.2 Long Acting Insulin
    • 8.3.3 Premixed Insulin
    • 8.3.4 Other Insulin

9. Region - Global Diabetes Drugs Market

  • 9.1 North America
  • 9.2 Europe
  • 9.3 Asia Pacific
  • 9.4 The Middle East & Africa

10. Porters Five Forces

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11. Company Analysis

  • 11.1 Novo Nordisk
    • 11.1.1 Overview
    • 11.1.2 Recent Development & Strategies
    • 11.1.3 Financial Insights
  • 11.2 AstraZeneca plc
    • 11.2.1 Overview
    • 11.2.2 Recent Development & Strategies
    • 11.2.3 Financial Insights
  • 11.3 Biocon
    • 11.3.1 Overview
    • 11.3.2 Recent Development & Strategies
    • 11.3.3 Financial Insights
  • 11.4 Sanofi
    • 11.4.1 Overview
    • 11.4.2 Recent Development & Strategies
    • 11.4.3 Financial Insights
  • 11.5 Eli Lilly
    • 11.5.1 Overview
    • 11.5.2 Recent Development & Strategies
    • 11.5.3 Financial Insights
  • 11.6 Johnson & Johnson
    • 11.6.1 Overview
    • 11.6.2 Recent Development & Strategies
    • 11.6.3 Financial Insights
  • 11.7 Bristol Myers Squibb Co.
    • 11.7.1 Overview
    • 11.7.2 Recent Development & Strategies
    • 11.7.3 Financial Insights